Alliance Global Partners analyst James Molloy initiates coverage on Chromocell Therapeutics (AMEX:CHRO) with a Buy rating.
Alliance Global Partners Initiates Coverage On Chromocell Therapeutics With Buy Rating
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.